Inflammatory Disease Clinical Trial
— EOSMODICOfficial title:
EOS MODIC : Inflammatory Disc Disease: Description of Statics by EOS Imaging and Evaluation of the Efficacy of Intradiscal Corticosteroid Infiltration
NCT number | NCT05022017 |
Other study ID # | EOS MODIC |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | May 3, 2021 |
Est. completion date | April 26, 2023 |
Verified date | April 2023 |
Source | Groupe Hospitalier Paris Saint Joseph |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Inflammatory disc disease or Modic 1 disc disease is a radiological entity first described by Modic in 1988 and corresponds to an inflammatory signal on MRI defined by the presence of a T2-weighted hypersignal and a T1-weighted hyposignal of the vertebral endplates adjacent to a pathological disc. The presence of these radiological abnormalities are significantly associated with chronic low back pain, the therapeutic management of which may include lumbar rehabilitation, rigid corset, spinal infiltrations and surgical treatment. Corticosteroid infiltration of the pathological intervertebral disc (intradiscal infiltration) has been evaluated in low back pain due to Modic 1 disc disease with short-term efficacy. The clinical response to this infiltration is not always optimal and to date in the literature, no predictive factor of response has been identified.
Status | Completed |
Enrollment | 100 |
Est. completion date | April 26, 2023 |
Est. primary completion date | June 3, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient whose age = 18 years - French speaking patient - Patient hospitalized in the rheumatology department of GHPSJ between 01/01/2014 and 31/12/2020 for MODIC 1 - Patients who received as part of their management an intra-disc infiltration with hydrocortancyl. Exclusion Criteria: - Patient under guardianship or curators - Patient deprived of liberty - Patient under court protection - Patient objecting to the use of his data for this research - Patient having benefited from another infiltration between the intradiscal infiltration and the collection of efficacy data at 3 months. |
Country | Name | City | State |
---|---|---|---|
France | Groupe Hospitalier Paris Saint Joseph | Paris | Ile-de-France |
Lead Sponsor | Collaborator |
---|---|
Groupe Hospitalier Paris Saint Joseph |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluate the effectiveness of the intra-disc infiltration at 3 months on the pain felt by the patient. | Percentage of patients with improved low back pain defined as a decrease in Visual Analogue Scale (VAS) pain >3 at 3 months after intradiscal infiltration compared to VAS at admission.
VAS scale : minimum score 0 (no pain) / higher score 10 (greater pain intensity) |
3 months | |
Secondary | Change in analgesic consumption (Level 1, Level 2, Level 3 and NSAIDs) at 3 months. | Consumption of level 1, 2 or 3 painkillers and NSAIDs in the previous week (number of doses per day and per week). | 3 months | |
Secondary | Describe the parameters of spinal statics in the frontal planes in Modic 1 disc disease. | Distribution of the values of the parameters of the spinal statics in the sagittal plane (sacral slope, pelvic incidence, pelvic version, lumbar lordosis, Roussouly classification) and in the frontal plane (cobb angle). | 3 months | |
Secondary | Compare the parameters of spinal statics according to the different stages of Modic 1 disc disease | Distribution of the values of spinal statics parameters in the sagittal plane (sacral slope, pelvic incidence, pelvic version, lumbar lordosis, Roussouly classification) and in the frontal plane (cobb angle) according to the presence of low lumbar (L4L5 L5S1) or high lumbar (L1L2 L2L3 L3L4) disc disease. | 3 months | |
Secondary | Predictive factors (clinical and radiological) of the effectiveness of intra-disc infiltration | Correlation between pain improvement 3 months after infiltration and the type of disc disease (cobb scoliosis > 10°) as well as the parameters of spinal statics in the sagittal and frontal planes and the type of disc damage according to the Pfirmann classification | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03964324 -
NO Measurements in Screening for Asthma and OSA, in Patients With Severe Snoring
|
N/A | |
Recruiting |
NCT03963648 -
NO Measurements in Screening for Asthma and OSA, in Patients With CRSwNP
|
N/A | |
Not yet recruiting |
NCT04997343 -
Neurophysiological Assessment in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT01695876 -
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT05546788 -
Hydroxylated Polymethoxy Flavones Solid Dispersion in Treatment of Periodontitis
|
Phase 1 | |
Recruiting |
NCT03651518 -
Personalized Therapies in Inflammatory Complex Disease
|
Phase 2 | |
Not yet recruiting |
NCT05544448 -
In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases
|
N/A | |
Completed |
NCT02552004 -
Assessment of Intraoperative Probe-based Confocal Laser Endomicroscopy in Digestive and Endocrine Surgery: a Pilot Study
|
N/A | |
Completed |
NCT04368494 -
Exercise Therapy in Patients With Axial Spondyloarthritis
|
N/A | |
Completed |
NCT03878134 -
Translational Development of Photon-counting CT Imaging
|
N/A | |
Recruiting |
NCT06059989 -
inDuctIon tREatment With subCuTaneous Infliximab for Crohn's Disease
|
Phase 3 | |
Completed |
NCT02959138 -
Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function
|
Phase 1 | |
Active, not recruiting |
NCT04565821 -
Feasibility Study to Assess a Trans-nasal Intestinal Potential Difference Probe
|
N/A | |
Recruiting |
NCT05509075 -
Nutraceuticals and Functional Foods
|
||
Active, not recruiting |
NCT06448052 -
Umbilical Cord Mesenchymal Stem Cell for Aging-related Low-grade Inflammation
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05944822 -
Pro-inflammatory Cytokines in Case of Essure®
|
||
Completed |
NCT05115370 -
Vaccination Perception in Inflammatory Conditions - Flu, Pneumonia and COVID-19
|
||
Active, not recruiting |
NCT03604406 -
The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept
|
Phase 2 | |
Recruiting |
NCT05364294 -
Molecular Diagnosis of Systemic Autoinflammatory Diseases
|
||
Recruiting |
NCT05860400 -
Efficacy and Safety of Comprehensive Treatment in Patients With IR-CAD: a Self-controlled Cohort Study
|